ESMO interim update on new targeted therapies in the first-line and at relapse of CLL

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia - European Society for Medical Oncology (ESMO)

- The update covers the approval of time-limited ibrutinib–venetoclax in first line and new data on MRD-driven treatment.

- It also covers the approval of the BTKi zanubrutinib in both treatment-naive and relapsed or refractory CLL.

- Additional evidence on the time-limited combination of venetoclax plus an anti-CD20 antibody in the first line are included.

- Options for later-line treatments based on the type of prior lines of treatment are also included.

- Recommendations are based on available scientific data and the authors’ collective expert opinion.


Read full Guideline